A Phase 3 interventional study of IGIV-C in Myasthenia Gravis Exacerbations, sponsored by Grifols Therapeutics LLC. Completed at 31 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Myasthenia Gravis with a site in France — 20 open to participants now, 32 under way, 16 of them phase 3. Myasthenia Gravis · France.
Among the 56 studies in Myasthenia Gravis with a site in France, this one is the 37th largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2015, is one of 27 in phase 3, and was the 7th registered.
330 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →20 of the 56 studies in Myasthenia Gravis with a site in France are open now. Recruiting first, the newest first:
Ad scientiam · Sites in France, Denmark, Germany and 2 more countries
Ages 18+
UCB Biopharma SRL · Sites in France, United States, China and 4 more countries
Ages 18+
Amgen · Sites in France, United States, Argentina and 5 more countries
Ages 2–17
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
UCB Biopharma SRL · Sites in France, United States, Canada and 6 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 30 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 123 across the 44 interventional studies, 88 across the 12 observational. Of the 24 that completed or were terminated, 13 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 3 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
8 of the studies in Myasthenia Gravis with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT06414954NMD Pharma A/SSafety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | 2026-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 56 studies in Myasthenia Gravis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.
The study consisted of a single dose course of IGIV-C treatment followed by 28-days of post-infusion assessments. The total duration of study participation for each subject was up to 28 ± 2 days. Approximately 50 subjects, ages 18 or greater, were planned to be enrolled in the study and receive a single, total dose of 2 g/kg of IGIV-C over 2 consecutive days (dose of 1 g/kg per day) across multiple centers in Argentina, Canada, Europe, and South Africa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.
Biological: IGIV-C
An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
Change in Quantitative Myasthenia Gravis (QMG) Scale Score
Mean Change in Quantitative Myasthenia Gravis (QMG) Scale Score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG Scale are 0 and 39, respectively, and a higher score means a worse outcome.
Time frame: From Baseline (Day 0) to Day 14
Percentage of Subjects With Clinical Improvement Assessed by QMG
The percentage of subjects with clinical improvement at Day 14 as assessed by the Quantitative Myasthenia Gravis (QMG) scale in the Evaluable population is presented, in which clinical improvement is defined as at least 3-point decrease in QMG score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG scale are 0 and 39, respectively, and a higher score means a worse outcome.
Time frame: Baseline (Day 0) to Day 14
Percentage of Subjects With Clinical Improvement Assessed by MG-Activities of Daily Living (MG-ADL) Scale
The percentage of subjects with clinical improvement at Day 14 as assessed by the MG-ADL Scale in the Evaluable population is presented, in which clinical improvement is defined as at least 2-point decrease in the MG-ADL score. The minimum and maximum scores of the MG-DAL scale are 0 and 24, respectively, and a higher score means a worse outcome.
Time frame: Baseline (Day 0) to Day 14
Percentage of Subjects With Clinical Improvement Assessed by the MG Composite
The percentage of subjects with clinical improvement at Day 14 as assessed by the MG Composite scale in the Evaluable population is presented in which clinical improvement is defined as at least 3-point decrease in the MG Composite score. The minimum and maximum scores of the MG Composite scale are 0 and 50, respectively, with a higher score meaning a worse outcome.
Time frame: Baseline (Day 0) to Day 14
| Milestone | IGIV-C Treatment |
|---|---|
| Started | 49 |
| Completed | 46 |
| Not completed | 3 |
Mean Change in Quantitative Myasthenia Gravis (QMG) Scale Score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG Scale are 0 and 39, respectively, and a higher score means a worse outcome.
| score on a scale | IGIV-C Treatment |
|---|---|
| Change in Quantitative Myasthenia Gravis (QMG) Scale Score | -6.4 ± 5.15 |
The percentage of subjects with clinical improvement at Day 14 as assessed by the Quantitative Myasthenia Gravis (QMG) scale in the Evaluable population is presented, in which clinical improvement is defined as at least 3-point decrease in QMG score from Baseline (Day 0) to Day 14. The minimum and maximum scores of the QMG scale are 0 and 39, respectively, and a higher score means a worse outcome.
| Participants | IGIV-C Treatment |
|---|---|
| Percentage of Subjects With Clinical Improvement Assessed by QMG | 33 |
The percentage of subjects with clinical improvement at Day 14 as assessed by the MG-ADL Scale in the Evaluable population is presented, in which clinical improvement is defined as at least 2-point decrease in the MG-ADL score. The minimum and maximum scores of the MG-DAL scale are 0 and 24, respectively, and a higher score means a worse outcome.
| Participants | IGIV-C Treatment |
|---|---|
| Percentage of Subjects With Clinical Improvement Assessed by MG-Activities of Daily Living (MG-ADL) Scale | 38 |
The percentage of subjects with clinical improvement at Day 14 as assessed by the MG Composite scale in the Evaluable population is presented in which clinical improvement is defined as at least 3-point decrease in the MG Composite score. The minimum and maximum scores of the MG Composite scale are 0 and 50, respectively, with a higher score meaning a worse outcome.
| Participants | IGIV-C Treatment |
|---|---|
| Percentage of Subjects With Clinical Improvement Assessed by the MG Composite | 37 |
Collected over Subjects with MG exacerbations not attributable to an infection or change in medication were planned to receive 2 g/kg of IGIV-C on Day 0 (Baseline) and on Day 1 (dosed as 1 g/kg per day), followed by 28 days of post-infusion assessments. During this 30-day period, the adverse event data were collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGIV-C Treatment | 0/49 (0%) | 0/49 (0%) | 30/49 (61.2%) |
| Event | IGIV-C Treatment |
|---|---|
| HeadacheNervous system disorders | 19/49 |
| PyrexiaGeneral disorders | 8/49 |
| UrticariaSkin and subcutaneous tissue disorders | 4/49 |
| Influenza like illnessGeneral disorders | 3/49 |
| VomitingGastrointestinal disorders | 3/49 |
| RashSkin and subcutaneous tissue disorders | 3/49 |
The demographic data are from the Safety population that consisted of all 49 subjects who were infused with any amount of study drug.
| Age, Categorical(Participants) | IGIV-C Treatment |
|---|---|
| <=18 years | 2 |
| Between 18 and 65 years | 40 |
| >=65 years | 7 |
| Age, Continuous(year) | IGIV-C Treatment |
|---|---|
| Mean | 47.3 ± 15.22 |
| Sex: Female, Male(Participants) | IGIV-C Treatment |
|---|---|
| Female | 34 |
| Male | 15 |
| Race (NIH/OMB)(Participants) | IGIV-C Treatment |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 44 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | IGIV-C Treatment |
|---|---|
| Canada | 3 |
| Argentina | 3 |
| Latvia | 10 |
| Romania | 5 |
| Belgium | 6 |
| Czechia | 4 |
| Poland | 4 |
| South Africa | 2 |
| France | 2 |
| Russia | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2015, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2020, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous